flosequinan
Trade name: Manoplax
Small moleculewithdrawn
Approved
Dec 30, 1992
Flosequinan is a vasodilator developed for the treatment of heart failure. The drug was marketed under the name Manoplax, however it was withdrawn by the FDA decision since it increased congestive heart failure symptoms. The exact mechanism of flosequinan action is unknown, but there are studies reporting the inhibition of PDE3 activity. — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 1 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Timeline
1990s
- Dec 30, 1992
Earliest FDA Approval
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Unknown
Flosequinan is a potent direct-acting vasodilator agent which acts on both peripheral arterial and venous vessels, by interfering with the inositol-tri- phosphate/protein kinase C pathway.
Approval history
- withdrawnDec 30, 1992
Chemistry & pharmacology
Loading structure…
SMILES
CN1C=C([S+](C)[O-])C(=O)C2=C1C=C(F)C=C2- Mol. weight
- 239.266 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFlosequinan ↗
- NCATS6NB119DLU7 ↗
- ChEMBLCHEMBL1908307 ↗
Also known as
- 7-fluoro-1-methyl-3-methylsulfinyl-4-quinoline
- bts 49465
- bts-49465
- bts-49465
- bts-49465
- flosequinan
- flosequinan
- flosequinan
- flosequinan
- flosequinan
- flosequinan
- flosequinan
- flosequinan
- flosequinon
- manoplax
- manoplax
- manoplax
- manoplax
Organizations
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| The Boots Company | For profit | NDA | — |